← 返回首页
美国 · 经济杂志 · Markets Insider (Business Insider)

Allarta Life Science moves Canadian-developed type 1 diabetes cell therapy closer to the clinic with Breakthrough T1D award

来源:Markets Insider (Business Insider) · 美国 51 分钟前
Allarta Life Science moves Canadian-developed type 1 diabetes cell therapy closer to the clinic with Breakthrough T1D award
Markets Insider (Business Insider)

详细摘要

HAMILTON, Ont, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Allarta Life Science Inc. has received an award from Breakthrough T1D, the leading type 1 diabetes (T1D) research and advocacy…

HAMILTON, Ont, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Allarta Life Science Inc. has received an award from Breakthrough T1D, the leading type 1 diabetes (T1D) research and advocacy organization, for the next stage of development needed to bring Allarta’s immune-protective LifeSpheres™ hydrogel technology to clinical trials. Allarta® technology aims to make cell therapy more accessible to people living with T1D by protecting transplanted insulin-producing cells without the need for lifelong immune-suppressing drugs.

Dr. Harald Stover, Allarta’s CEO and a professor of chemistry at McMaster University for more than 30 years, co-founded the company in 2019 with Maria Antonakos, Chief Operating Officer, to advance the technology pioneered in the Stover lab. The announcement opened McMaster University’s Innovation Showcase at McMaster Innovation Park, where Allarta is headquartered.

Allarta’s work builds on more than a century of diabetes breakthroughs in Canada. Sir Frederick Banting and his colleagues helped discover insulin at the University of Toronto in 1921, and World Diabetes Day is observed each year on his birthday, November 14. In 2000, the University of Alberta’s Edmonton Protocol showed that transplanted insulin-producing cells could restore insulin production in people with T1D.

“Canada gave the world insulin,” said Dr. Stover. “With Breakthrough T1D’s award, our team is working toward the next step: a cell therapy without immune suppression that could help people with type 1 diabetes produce insulin.”

About 9.5 million people worldwide live with T1D, including 300,000 Canadians, according to Breakthrough T1D. Access to islet-cell transplantation is currently limited, in part because recipients require lifelong immunosuppressive medication. Allarta’s technology aims to address this barrier by physically protecting transplanted cells from immune attack while allowing them to survive, function and produce insulin.

“A transplant of insulin-producing cells can give…

This…

文章开头,摘自Markets Insider (Business Insider)。如需阅读全文,请前往媒体网站。

在 Markets Insider (Business Insider) 阅读全文 登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (markets.businessinsider.com)

推荐阅读